Katheeja Muhseena N.
SRF
-
Cancer Biology
-
MSc (Area): Bio-Medical science
-
katheejamuhseenan@yenepoya.edu.in
I completed my Master’s degree in Bio-Medical Science Subject from 2014 to 2016 at Nitte University Centre for Science education and research, Deralakatte, Mangaluru, India. In my master’s thesis, I worked on a project entitled “RELATIONSHIP OF VEGF POLYMORPHISMS AND DIABETIC RETINOPATHY IN PATIENTS WITH TYPE 2 DIABETES: A CASE STUDY”. I joined Yenepoya Research Centre in May, 2017 and working on Triple Negative Breast Cancer.
Experience
2 Years as JRF at Yenepoya Research centre
Awards/Honors
- Awarded Ph.D fellowship from Minority Welfare Department Directorate of Minorities Karnataka government in the year 2019
- Awarded 1st place in poster presentation titled as “Expression of BRCA1 and its inter mediator gene in Triple Negative Breast Cancer cell line” on National symposium “Cancer Prevention and Control by Health Promotion and Early detection on 24th April 2018” at Yenepoya Medical college, Deralakatte, Mangalore.
Research Interest/Area
Cell culture: Cell counting, Proliferation assay, Migration assay, live dead assay, MTT assay, cell cycle analysis, Immunophenotyping, Immunofluorescence and Immunocytochemistry
Molecular Biology : DNA extraction and quantification, RNA extraction and quantification, protein extraction and quantification, PCR(RT-PCR, Conventional PCR, Q-PCR), Gel electrophoresis, SDS-PHAGE, Western blotting, Chromatin-Immunoprecipitation assay, DAPI Staining and may Grunewald staining
Research
Breast cancer is an extremely diverse disease comprised of numerous sub classification. The classification is based on the histopathological nature, basic molecular etiology, and clinical behavior. It is widely known that triple-negative breast cancer (TNBC) is one of the most aggressive subtypes, characterized by deficient in expression of the estrogen receptor (ER), progesterone receptor (ER), and HER2. TNBC has been found that it has a poor prognosis, less survival rate and high metastasis value due to the absence of an identified therapeutic target and its biologically aggressive characteristics. The current focus of the study was to understand the role of BRCA1 and p53, the major effector kinase in Triple-Negative Breast cancer.